131 related articles for article (PubMed ID: 31488245)
1. Intraperitoneal ports placed at the time of bowel resection for treatment of ovarian cancer: Complications and surgical outcomes.
Kay AH; Urban RR; Gray HJ
Gynecol Oncol; 2019 Nov; 155(2):220-223. PubMed ID: 31488245
[TBL] [Abstract][Full Text] [Related]
2. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
Nica A; Covens A; Parra-Herran C; May T
Gynecol Oncol; 2020 Sep; 158(3):622-630. PubMed ID: 32561124
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Mueller JJ; Kelly A; Zhou Q; Iasonos A; Long Roche K; Sonoda Y; O'Cearbhaill RE; Zivanovic O; Chi DS; Gardner GJ
Gynecol Oncol; 2016 Dec; 143(3):496-503. PubMed ID: 27692668
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
5. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer.
Janco JM; Hacker MR; Konstantinopoulos PA; Cannistra SA; Awtrey CS
J Minim Invasive Gynecol; 2011; 18(5):629-33. PubMed ID: 21803662
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
Chambers LM; Son J; Radeva M; DeBernardo R
J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
[TBL] [Abstract][Full Text] [Related]
7. Complications associated with 9-10Fr venous access port use in adjuvant intraperitoneal chemotherapy after a cytoreductive surgery in ovarian cancer patients.
Milczek T; Klasa-Mazurkiewicz D; Wydra D
Adv Med Sci; 2015 Sep; 60(2):216-9. PubMed ID: 25863871
[TBL] [Abstract][Full Text] [Related]
8. It's not just for laparoscopy anymore: use of insufflation under ultrasound and fluoroscopic guidance by Interventional Radiologists for percutaneous placement of intraperitoneal chemotherapy catheters.
Henretta MS; Anderson CL; Angle JF; Duska LR
Gynecol Oncol; 2011 Nov; 123(2):342-5. PubMed ID: 21840583
[TBL] [Abstract][Full Text] [Related]
9. Morbidity of multiple bowel resection compared to single bowel resection after debulking surgery for ovarian cancer.
Tozzi R; Casarin J; Baysal A; Pinelli C; Matak L; Ghanbarzadeh N; Alazzam M; Garruto-Campanile R; Majd HS; Kilic Y; Morotti M
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():215-219. PubMed ID: 31326636
[TBL] [Abstract][Full Text] [Related]
10. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look".
Grette K; Long B; Finan MA; Rocconi RP
Gynecol Oncol; 2019 Aug; 154(2):290-293. PubMed ID: 31160072
[TBL] [Abstract][Full Text] [Related]
12. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
Ivy JJ; Geller M; Pierson SM; Jonson AL; Argenta PA
Gynecol Oncol; 2009 Sep; 114(3):420-3. PubMed ID: 19560189
[TBL] [Abstract][Full Text] [Related]
13. Low rate of intraperitoneal port placement in ovarian cancer patients, a population-based assessment.
Buckingham L; Koenig A; Ko EM; Brensinger CM; Latif N; Hummel C; Zhang X; Morgan MA; Burger RA; Giuntoli Ii RL
Int J Gynecol Cancer; 2019 Sep; 29(7):1177-1181. PubMed ID: 31302627
[TBL] [Abstract][Full Text] [Related]
14. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
[TBL] [Abstract][Full Text] [Related]
15. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
[TBL] [Abstract][Full Text] [Related]
16. Rectosigmoidectomy and Douglas Peritonectomy in the Management of Serosal Implants in Advanced-Stage Ovarian Cancer Surgery: Survival and Surgical Outcomes.
Erkilinç S; Karataşli V; Demir B; Çakir İ; Can B; Karadeniz T; Gökçü M; Sanci M
Int J Gynecol Cancer; 2018 Nov; 28(9):1699-1705. PubMed ID: 30371561
[TBL] [Abstract][Full Text] [Related]
17. Complications associated with intraperitoneal chemotherapy catheters.
Makhija S; Leitao M; Sabbatini P; Bellin N; Almadrones L; Leon L; Spriggs DR; Barakat R
Gynecol Oncol; 2001 Apr; 81(1):77-81. PubMed ID: 11277654
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
Bruixola G; Domingo S; Díaz R; Caballero J; Palomar L; De La Cueva H; Santaballa A
Int J Gynecol Cancer; 2015 Feb; 25(2):214-21. PubMed ID: 25415075
[TBL] [Abstract][Full Text] [Related]
19. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer.
Gillette-Cloven N; Burger RA; Monk BJ; McMeekin DS; Vasilev S; DiSaia PJ; Kohler MF
J Am Coll Surg; 2001 Dec; 193(6):626-32. PubMed ID: 11768679
[TBL] [Abstract][Full Text] [Related]
20. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
